Tau protein is an intrinsically disordered microtubule-binding protein that forms ordered β-sheet cores upon hyperphosphorylation at sites including Ser202/Thr205 and Ser396/Ser404, driving Alzheimer's neurofibrillary tangles

Research question

Visualize the structure of tau protein (MAPT, UniProt P10636). Summarize its role in Alzheimer's disease and the phosphorylation sites that drive aggregation. Cite structural biology papers.

Key findings

1. Cryo-EM structures solved by Fitzpatrick et al. revealed that tau filaments from Alzheimer's brains form an ordered core of approximately 79 amino acids (residues 306–378) arranged as C-shaped protofilaments with β-sheets and a β-helix motif, distinct from tau folds in other tauopathies [1,2,3].
2. The AT8 epitope (Ser202/Thr205) represents one of the earliest phosphorylation markers of tau pathology, appearing in a priming and feedback cascade that establishes the pathological phosphorylation pattern [4].
3. The PHF-1 epitope (Ser396/Ser404) in the C-terminal region near microtubule-binding domains is highly enriched in paired helical filament tau and correlates with the severity of neuronal cytopathology across disease stages [4,5,6].
4. GSK-3β directly phosphorylates multiple proline-directed sites on tau and catalyzes aggregation into AD-like filaments, establishing a mechanistic link between kinase activity and pathological assembly [6,7,8].
5. Cryo-EM structures of AD tau filaments bound to PET tracers like MK-6240 and flortaucipir show that these diagnostic ligands bind within cavities formed by the ordered tau core, explaining their utility for in vivo imaging of tau pathology [9,10].

Evidence

Clinical implications

• PET tracers targeting the structured tau core (e.g., MK-6240, flortaucipir) can stage tau pathology in vivo, supporting diagnosis and monitoring of Alzheimer's disease progression.
• AT8 and PHF-1 phospho-epitopes serve as biomarkers for early and late tau pathology respectively, with potential utility in clinical trial patient stratification.
• GSK-3β inhibition represents a rational therapeutic strategy to prevent tau hyperphosphorylation and aggregation, though clinical efficacy remains unproven in Phase 3 trials.

Limitations

• No primary PubMed, ClinicalTrials.gov, or other external database sources were independently verified during this session; all citations derive from the agent's internal knowledge and transcript references only.
• Cryo-EM structures represent post-mortem end-stage aggregates and may not capture early oligomeric intermediates or soluble phospho-tau species that drive toxicity.
• The causal relationship between specific phosphorylation sites and aggregation is correlative in human tissue; experimental evidence linking individual sites to pathogenicity comes largely from in vitro and animal models.
• Tau isoform complexity (six brain isoforms from alternative splicing) is not fully addressed; most structural studies focus on the longest 2N4R isoform.
• Kinase specificity in vivo is unclear; multiple kinases (GSK-3β, CDK5, others) phosphorylate overlapping sites, and compensatory mechanisms may limit single-kinase therapeutic targeting.

Open questions

• Which phosphorylation sites are necessary and sufficient to nucleate tau aggregation in human neurons?
• Do soluble oligomeric tau species or insoluble filaments drive neurodegeneration, and how does phosphorylation status differ between these pools?
• Can structure-based design yield small molecules that disrupt the ordered tau core or prevent seeding?
• What accounts for the prion-like spreading of tau pathology across brain regions, and does phosphorylation status influence cell-to-cell transmission?
• Why do PET tracers show variable retention across tauopathies if tau folds are disease-specific, and can next-generation tracers discriminate Alzheimer's from other tauopathies?